Health Care/Hospitals, News

USD 28.28 Bn growth expected in Vaccines Market — Driven by increased funding for vaccine development and new vaccine launches

NEW YORK, Sept. 28, 2022 /PRNewswire/ — The “Vaccines Market by Type and Geography – Forecast and Analysis 2022-2026” report has been added to Technavio’s offering. The report expects the market size to grow by USD 28.28 billion between 2021 and 2026, accelerating at a CAGR of 4.13% during the forecast period. The report provides a comprehensive analysis of the drivers, trends, and challenges influencing the growth of the market. Download PDF Report Sample

The market is driven by increased funding for vaccine development and new vaccine launches. The rising prevalence of various diseases has necessitated vaccine manufacturers to invest heavily in their technical capabilities to develop new drugs. Pharmaceutical companies are partnering with the government, researchers, manufacturers, purchasers, and policymakers to deliver successful vaccine innovations. In addition, governments across the world are increasing the allocation of funds toward the development and launch of new vaccines. For instance, in March 2021, the Russian Direct Investment Fund (RDIF) proposed to invest approximately USD 10 million in a Hyderabad-based company Virchow Biotech, to produce up to 200 million doses of the Sputnik V vaccine in India. Many such developments are expected to foster the growth of the global vaccines market during the forecast period. Learn more about the other factors driving the growth of the market. Buy Report Now

As per Technavio, the development of nanoparticle vaccines will have a positive impact on the market and contribute to its growth significantly over the forecast period. This research report also analyzes other significant trends and market drivers that will influence market growth.

Vaccines Market: Development of nanoparticle vaccines

The traditional way of creating vaccines includes the development of vaccines from protein subunits and killed pathogens and some vaccines are based on live attenuated organisms. These vaccines have the risk of regaining their pathogenicity under certain immunocompromised conditions. To overcome such challenges, researchers and pharmaceutical companies are focusing on the development of nanoparticle-based vaccines. These have higher efficacies and can have targeted deliveries to achieve desired immune responses. Such benefits are increasing investments in the R&D of nanoparticle-based vaccines globally. This trend is expected to have a positive impact on the growth of the global vaccines market during the forecast period.

Vaccines Market: Segmentation Analysis

This market research report segments the vaccines market by type (prophylactic vaccines and therapeutic vaccines) and geography (North America, Europe, Asia, and the Rest of the World (ROW)).

The market will observe significant growth in the prophylactic vaccines segment during the forecast period. The segment is driven by the increasing demand for prophylactic vaccines to treat various viral diseases such as Hepatitis B, human papillomavirus (HPV), whooping cough, pneumococcal disease, meningococcal disease, and shingles.

The North American region led the vaccines market in 2021, followed by Europe, Asia, and the Rest of the World (ROW) respectively. During the forecast period, the North American region is expected to register the highest incremental growth. The growth of the regional market can be attributed to the increasing number of immunization programs and the strong prevalence of infectious diseases such as influenza, hepatitis A, hepatitis B, HIV, measles, malaria, and tuberculosis, and non-infectious diseases such as cancer.

Technavio’s sample reports are free of charge and contain multiple sections of the report, such as the market size and forecast, drivers, challenges, trends, and more. Request Sample Report Here

Some of the key topics covered in the report include:

Market Drivers

Market Challenges

Market Trends

Vendor Landscape

  • Vendors covered
  • Vendor classification
  • Market positioning of vendors
  • Competitive scenario
Related Reports:

Vaccines Market Scope

Report Coverage

Details

Page number

120

Base year

2021

Forecast period

2022-2026

Growth momentum & CAGR

Accelerate at a CAGR of 4.13%

Market growth 2022-2026

USD 28.28 billion

Market structure

Fragmented

YoY growth (%)

4.0

Regional analysis

North America, Europe, Asia, and Rest of World (ROW)

Performing market contribution

North America at 48%

Key consumer countries

US, Canada, Germany, UK, and France

Competitive landscape

Leading companies, competitive strategies, consumer engagement scope

Companies profiled

Astellas Pharma Inc., AstraZeneca Plc, Bavarian Nordic AS, Bharat Biotech Ltd., BrightPath Biotherapeutics Co. Ltd., CSL Ltd., Daiichi Sankyo Co. Ltd., Emergent BioSolutions Inc., GlaxoSmithKline Plc, Gradalis Inc., Inovio Pharmaceuticals Inc., Johnson and Johnson, Merck and Co. Inc., Mitsubishi Chemical Holdings Corp., Novavax Inc., Pfizer Inc., Sanofi, Serum Institute of India Pvt. Ltd., Takeda Pharmaceutical Co. Ltd., and Valneva SE

Market Dynamics

Parent market analysis, Market growth inducers and obstacles, Fast-growing and slow-growing segment analysis, COVID-19 impact and future consumer dynamics, and market condition analysis for the forecast period.

Customization purview

If our report has not included the data that you are looking for, you can reach out to our analysts and get segments customized.

Table of contents:

1 Executive Summary

  • 1.1 Market overview 
    • Exhibit 01: Executive Summary – Chart on Market Overview
    • Exhibit 02: Executive Summary – Data Table on Market Overview
    • Exhibit 03: Executive Summary – Chart on Global Market Characteristics
    • Exhibit 04: Executive Summary – Chart on Market by Geography
    • Exhibit 05: Executive Summary – Chart on Market Segmentation by Type
    • Exhibit 06: Executive Summary – Chart on Incremental Growth
    • Exhibit 07: Executive Summary – Data Table on Incremental Growth
    • Exhibit 08: Executive Summary – Chart on Vendor Market Positioning

2 Market Landscape

  • 2.1 Market ecosystem 
    • Exhibit 09: Parent market
    • Exhibit 10: Market Characteristics

3 Market Sizing

  • 3.1 Market definition 
    • Exhibit 11: Offerings of vendors included in the market definition
  • 3.2 Market segment analysis 
    • Exhibit 12: Market segments
  • 3.3 Market size 2021
  • 3.4 Market outlook: Forecast for 2021-2026 
    • Exhibit 13: Chart on Global – Market size and forecast 2021-2026 ($ billion)
    • Exhibit 14: Data Table on Global – Market size and forecast 2021-2026 ($ billion)
    • Exhibit 15: Chart on Global Market: Year-over-year growth 2021-2026 (%)
    • Exhibit 16: Data Table on Global Market: Year-over-year growth 2021-2026 (%)

4 Five Forces Analysis

  • 4.1 Five forces summary 
    • Exhibit 17: Five forces analysis – Comparison between2021 and 2026
  • 4.2 Bargaining power of buyers 
    • Exhibit 18: Chart on Bargaining power of buyers – Impact of key factors 2021 and 2026
  • 4.3 Bargaining power of suppliers 
    • Exhibit 19: Bargaining power of suppliers – Impact of key factors in 2021 and 2026
  • 4.4 Threat of new entrants 
    • Exhibit 20: Threat of new entrants – Impact of key factors in 2021 and 2026
  • 4.5 Threat of substitutes 
    • Exhibit 21: Threat of substitutes – Impact of key factors in 2021 and 2026
  • 4.6 Threat of rivalry 
    • Exhibit 22: Threat of rivalry – Impact of key factors in 2021 and 2026
  • 4.7 Market condition 
    • Exhibit 23: Chart on Market condition – Five forces 2021 and 2026

5 Market Segmentation by Type

  • 5.1 Market segments 
    • Exhibit 24: Chart on Type – Market share 2021-2026 (%)
    • Exhibit 25: Data Table on Type – Market share 2021-2026 (%)
  • 5.2 Comparison by Type 
    • Exhibit 26: Chart on Comparison by Type
    • Exhibit 27: Data Table on Comparison by Type
  • 5.3 Prophylactic vaccines – Market size and forecast 2021-2026 
    • Exhibit 28: Chart on Prophylactic vaccines – Market size and forecast 2021-2026 ($ billion)
    • Exhibit 29: Data Table on Prophylactic vaccines – Market size and forecast 2021-2026 ($ billion)
    • Exhibit 30: Chart on Prophylactic vaccines – Year-over-year growth 2021-2026 (%)
    • Exhibit 31: Data Table on Prophylactic vaccines – Year-over-year growth 2021-2026 (%)
  • 5.4 Therapeutic vaccines – Market size and forecast 2021-2026
    • Exhibit 32: Chart on Therapeutic vaccines – Market size and forecast 2021-2026 ($ billion)
    • Exhibit 33: Data Table on Therapeutic vaccines – Market size and forecast 2021-2026 ($ billion)
    • Exhibit 34: Chart on Therapeutic vaccines – Year-over-year growth 2021-2026 (%)
    • Exhibit 35: Data Table on Therapeutic vaccines – Year-over-year growth 2021-2026 (%)
  • 5.5 Market opportunity by Type 
    • Exhibit 36: Market opportunity by Type ($ billion)

6 Customer Landscape

  • 6.1 Customer landscape overview 
    • Exhibit 37: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria

7 Geographic Landscape

  • 7.1 Geographic segmentation 
    • Exhibit 38: Chart on Market share by geography 2021-2026 (%)
    • Exhibit 39: Data Table on Market share by geography 2021-2026 (%)
  • 7.2 Geographic comparison 
    • Exhibit 40: Chart on Geographic comparison
    • Exhibit 41: Data Table on Geographic comparison
  • 7.3 North America – Market size and forecast 2021-2026
    • Exhibit 42: Chart on North America – Market size and forecast 2021-2026 ($ billion)
    • Exhibit 43: Data Table on North America – Market size and forecast 2021-2026 ($ billion)
    • Exhibit 44: Chart on North America – Year-over-year growth 2021-2026 (%)
    • Exhibit 45: Data Table on North America – Year-over-year growth 2021-2026 (%)
  • 7.4 Europe – Market size and forecast 2021-2026
    • Exhibit 46: Chart on Europe – Market size and forecast 2021-2026 ($ billion)
    • Exhibit 47: Data Table on Europe – Market size and forecast 2021-2026 ($ billion)
    • Exhibit 48: Chart on Europe – Year-over-year growth 2021-2026 (%)
    • Exhibit 49: Data Table on Europe – Year-over-year growth 2021-2026 (%)
  • 7.5 Asia – Market size and forecast 2021-2026 
    • Exhibit 50: Chart on Asia – Market size and forecast 2021-2026 ($ billion)
    • Exhibit 51: Data Table on Asia – Market size and forecast 2021-2026 ($ billion)
    • Exhibit 52: Chart on Asia – Year-over-year growth 2021-2026 (%)
    • Exhibit 53: Data Table on Asia – Year-over-year growth 2021-2026 (%)
  • 7.6 Rest of World (ROW) – Market size and forecast 2021-2026
    • Exhibit 54: Chart on Rest of World (ROW) – Market size and forecast 2021-2026 ($ billion)
    • Exhibit 55: Data Table on Rest of World (ROW) – Market size and forecast 2021-2026 ($ billion)
    • Exhibit 56: Chart on Rest of World (ROW) – Year-over-year growth 2021-2026 (%)
    • Exhibit 57: Data Table on Rest of World (ROW) – Year-over-year growth 2021-2026 (%)
  • 7.7 US – Market size and forecast 2021-2026
    • Exhibit 58: Chart on US – Market size and forecast 2021-2026 ($ billion)
    • Exhibit 59: Data Table on US – Market size and forecast 2021-2026 ($ billion)
    • Exhibit 60: Chart on US – Year-over-year growth 2021-2026 (%)
    • Exhibit 61: Data Table on US – Year-over-year growth 2021-2026 (%)
  • 7.8 Germany – Market size and forecast 2021-2026
    • Exhibit 62: Chart on Germany – Market size and forecast 2021-2026 ($ billion)
    • Exhibit 63: Data Table on Germany – Market size and forecast 2021-2026 ($ billion)
    • Exhibit 64: Chart on Germany – Year-over-year growth 2021-2026 (%)
    • Exhibit 65: Data Table on Germany – Year-over-year growth 2021-2026 (%)
  • 7.9 UK – Market size and forecast 2021-2026
    • Exhibit 66: Chart on UK – Market size and forecast 2021-2026 ($ billion)
    • Exhibit 67: Data Table on UK – Market size and forecast 2021-2026 ($ billion)
    • Exhibit 68: Chart on UK – Year-over-year growth 2021-2026 (%)
    • Exhibit 69: Data Table on UK – Year-over-year growth 2021-2026 (%)
  • 7.10 Canada – Market size and forecast 2021-2026
    • Exhibit 70: Chart on Canada – Market size and forecast 2021-2026 ($ billion)
    • Exhibit 71: Data Table on Canada – Market size and forecast 2021-2026 ($ billion)
    • Exhibit 72: Chart on Canada – Year-over-year growth 2021-2026 (%)
    • Exhibit 73: Data Table on Canada – Year-over-year growth 2021-2026 (%)
  • 7.11 France – Market size and forecast 2021-2026
    • Exhibit 74: Chart on France – Market size and forecast 2021-2026 ($ billion)
    • Exhibit 75: Data Table on France – Market size and forecast 2021-2026 ($ billion)
    • Exhibit 76: Chart on France – Year-over-year growth 2021-2026 (%)
    • Exhibit 77: Data Table on France – Year-over-year growth 2021-2026 (%)
  • 7.12 Market opportunity by geography 
    • Exhibit 78: Market opportunity by geography ($ billion)

8 Drivers, Challenges, and Trends

  • 8.1 Market drivers
  • 8.2 Market challenges
  • 8.3 Impact of drivers and challenges 
    • Exhibit 79: Impact of drivers and challenges in 2021 and 2026
  • 8.4 Market trends

9 Vendor Landscape

  • 9.1 Overview
  • 9.2 Vendor landscape 
    • Exhibit 80: Overview on Criticality of inputs and Factors of differentiation
  • 9.3 Landscape disruption 
    • Exhibit 81: Overview on factors of disruption
  • 9.4 Industry risks 
    • Exhibit 82: Impact of key risks on business

10 Vendor Analysis

  • 10.1 Vendors covered 
    • Exhibit 83: Vendors covered
  • 10.2 Market positioning of vendors 
    • Exhibit 84: Matrix on vendor position and classification
  • 10.3 Astellas Pharma Inc. 
    • Exhibit 85: Astellas Pharma Inc. – Overview
    • Exhibit 86: Astellas Pharma Inc. – Product / Service
    • Exhibit 87: Astellas Pharma Inc. – Key news
    • Exhibit 88: Astellas Pharma Inc. – Key offerings
  • 10.4 AstraZeneca Plc 
    • Exhibit 89: AstraZeneca Plc – Overview
    • Exhibit 90: AstraZeneca Plc – Product / Service
    • Exhibit 91: AstraZeneca Plc – Key news
    • Exhibit 92: AstraZeneca Plc – Key offerings
  • 10.5 Bavarian Nordic AS 
    • Exhibit 93: Bavarian Nordic AS – Overview
    • Exhibit 94: Bavarian Nordic AS – Product / Service
    • Exhibit 95: Bavarian Nordic AS – Key news
    • Exhibit 96: Bavarian Nordic AS – Key offerings
  • 10.6 Bharat Biotech Ltd. 
    • Exhibit 97: Bharat Biotech Ltd. – Overview
    • Exhibit 98: Bharat Biotech Ltd. – Product / Service
    • Exhibit 99: Bharat Biotech Ltd. – Key news
    • Exhibit 100: Bharat Biotech Ltd. – Key offerings
  • 10.7 BrightPath Biotherapeutics Co. Ltd. 
    • Exhibit 101: BrightPath Biotherapeutics Co. Ltd. – Overview
    • Exhibit 102: BrightPath Biotherapeutics Co. Ltd. – Product / Service
    • Exhibit 103: BrightPath Biotherapeutics Co. Ltd. – Key offerings
  • 10.8 CSL Ltd. 
    • Exhibit 104: CSL Ltd. – Overview
    • Exhibit 105: CSL Ltd. – Business segments
    • Exhibit 106: CSL Ltd. – Key news
    • Exhibit 107: CSL Ltd. – Key offerings
    • Exhibit 108: CSL Ltd. – Segment focus
  • 10.9 Daiichi Sankyo Co. Ltd. 
    • Exhibit 109: Daiichi Sankyo Co. Ltd. – Overview
    • Exhibit 110: Daiichi Sankyo Co. Ltd. – Business segments
    • Exhibit 111: Daiichi Sankyo Co. Ltd. – Key news
    • Exhibit 112: Daiichi Sankyo Co. Ltd. – Key offerings
    • Exhibit 113: Daiichi Sankyo Co. Ltd. – Segment focus
  • 10.10 Emergent BioSolutions Inc. 
    • Exhibit 114: Emergent BioSolutions Inc. – Overview
    • Exhibit 115: Emergent BioSolutions Inc. – Product / Service
    • Exhibit 116: Emergent BioSolutions Inc. – Key news
    • Exhibit 117: Emergent BioSolutions Inc. – Key offerings
  • 10.11 GlaxoSmithKline Plc 
    • Exhibit 118: GlaxoSmithKline Plc – Overview
    • Exhibit 119: GlaxoSmithKline Plc – Business segments
    • Exhibit 120: GlaxoSmithKline Plc – Key news
    • Exhibit 121: GlaxoSmithKline Plc – Key offerings
    • Exhibit 122: GlaxoSmithKline Plc – Segment focus
  • 10.12 Gradalis Inc. 
    • Exhibit 123: Gradalis Inc. – Overview
    • Exhibit 124: Gradalis Inc. – Product / Service
    • Exhibit 125: Gradalis Inc. – Key offerings

11 Appendix

  • 11.1 Scope of the report
  • 11.2 Inclusions and exclusions checklist 
    • Exhibit 126: Inclusions checklist
    • Exhibit 127: Exclusions checklist
  • 11.3 Currency conversion rates for US$ 
    • Exhibit 128: Currency conversion rates for US$
  • 11.4 Research methodology 
    • Exhibit 129: Research methodology
    • Exhibit 130: Validation techniques employed for market sizing
    • Exhibit 131: Information sources
  • 11.5 List of abbreviations 
    • Exhibit 132: List of abbreviations
About Technavio

Technavio is a leading global technology research and advisory company. Their research and analysis focus on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions.

With over 500 specialized analysts, Technavio’s report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio’s comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.

Contacts

Technavio Research

Jesse Maida

Media & Marketing Executive

US: +1 844 364 1100

UK: +44 203 893 3200

Email: media@technavio.com

Website: www.technavio.com/

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/usd-28-28-bn-growth-expected-in-vaccines-market–driven-by-increased-funding-for-vaccine-development-and-new-vaccine-launches-301634257.html

SOURCE Technavio

Previous ArticleNext Article